G D’Haens

610 total citations
22 papers, 431 citations indexed

About

G D’Haens is a scholar working on Genetics, Epidemiology and Oncology. According to data from OpenAlex, G D’Haens has authored 22 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 9 papers in Epidemiology and 6 papers in Oncology. Recurrent topics in G D’Haens's work include Inflammatory Bowel Disease (15 papers), Microscopic Colitis (9 papers) and Colorectal Cancer Treatments and Studies (4 papers). G D’Haens is often cited by papers focused on Inflammatory Bowel Disease (15 papers), Microscopic Colitis (9 papers) and Colorectal Cancer Treatments and Studies (4 papers). G D’Haens collaborates with scholars based in Netherlands, Belgium and United States. G D’Haens's co-authors include Eric Van Cutsem, J. Załuski, Gunnar Folprecht, István Láng, O. Kisker, Christopher Stroh, Sabine Tejpar, Vladimir Moiseyenko, P. Rougier and Marjolijn Duijvestein and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

G D’Haens

21 papers receiving 410 citations

Peers

G D’Haens
Alfonso Yubero Spain
Robert S. Brody United States
K C Lakshmaiah India
Madhavan V. Pillai United States
Daniel E. Meyers Canada
Shun Yu United States
Wigdan Al-Sukhni Canada
S. Pugh United Kingdom
Sidrah Khan United States
Nanyan Rao China
Alfonso Yubero Spain
G D’Haens
Citations per year, relative to G D’Haens G D’Haens (= 1×) peers Alfonso Yubero

Countries citing papers authored by G D’Haens

Since Specialization
Citations

This map shows the geographic impact of G D’Haens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G D’Haens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G D’Haens more than expected).

Fields of papers citing papers by G D’Haens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G D’Haens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G D’Haens. The network helps show where G D’Haens may publish in the future.

Co-authorship network of co-authors of G D’Haens

This figure shows the co-authorship network connecting the top 25 collaborators of G D’Haens. A scholar is included among the top collaborators of G D’Haens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G D’Haens. G D’Haens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Zhigang, Wei Zhang, Bram Verstockt, et al.. (2025). Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease. Clinical Gastroenterology and Hepatology.
2.
Jonge, Catharina S. de, F de Voogd, Christianne J. Buskens, et al.. (2025). Quantified motility in Crohn’s disease to evaluate stricture composition using cine-MRI. British Journal of Radiology. 98(1172). 1245–1254. 1 indexed citations
3.
Dieren, Susan van, Marco W. Mundt, G D’Haens, et al.. (2024). Fistulizing Perianal Disease as a First Manifestation of Crohn’s Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 13(16). 4734–4734. 5 indexed citations
4.
Peyrin‐Biroulet, Laurent, Jean‐Frédéric Colombel, Édouard Louis, et al.. (2024). Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. SHILAP Revista de lepidopterología. 3(4). 539–550. 4 indexed citations
5.
6.
Adams, Alex, et al.. (2023). P803 Plasma N-glycan biomarkers predict patient Response to Vedolizumab treatment for Crohn’s Disease. Journal of Crohn s and Colitis. 17(Supplement_1). i936–i937. 2 indexed citations
7.
Bots, Steven, F de Voogd, Menno D. de Jong, et al.. (2021). Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm. Journal of Crohn s and Colitis. 16(4). 606–615. 34 indexed citations
8.
Dignaß, Axel, James O. Lindsay, Andreas Sturm, et al.. (2015). Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española). Revista de Gastroenterología de México. 80(1). 32–73. 3 indexed citations
9.
D’Haens, G, et al.. (2014). P386 Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease. Journal of Crohn s and Colitis. 8. S226–S226. 3 indexed citations
10.
Panaccione, Remo, J.F. Colombel, William J. Sandborn, et al.. (2009). P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy. Journal of Crohn s and Colitis. 3(1). S69–S70. 1 indexed citations
11.
Moreels, Tom G., Paul Pelckmans, Marc Peeters, et al.. (2009). Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium.. PubMed. 72(1). 17–25. 6 indexed citations
12.
Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri. Annals of Oncology. 19. 17–17. 11 indexed citations
13.
14.
Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Journal of Clinical Oncology. 26(15_suppl). 2–2. 281 indexed citations
15.
Panaccione, Remo, J.F. Colombel, William J. Sandborn, et al.. (2008). P002 ADALIMUMAB MAINTAINS LONG-TERM REMISSION IN CROHN'S DISEASE THROUGH 2 YEARS. 2(1). 5–5. 3 indexed citations
16.
Cunningham, David, G D’Haens, Jean‐Yves Douillard, et al.. (2008). A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results. Journal of Clinical Oncology. 26(15_suppl). 4028–4028. 26 indexed citations
17.
Ferrante, Marc, Gert De Hertogh, Tibor Hlavatý, et al.. (2006). Myenteric Plexitis in Unaffected Ileal Resection Margins Predicts Severe and Early Postoperative Crohn's Disease Recurrence. Inflammatory Bowel Diseases. 12. S29–S29. 4 indexed citations
18.
Elseviers, Monique, G D’Haens, Éric Lerebours, et al.. (2004). Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?. Clinical Nephrology. 61(2). 83–89. 35 indexed citations
19.
D’Haens, G, Alain Verstraete, Filip Baert, et al.. (1996). Osteoblast function is suppressed by oral methylprednisolone but not by budesonide CIR in active ileocolonic Crohn's disease. Gastroenterology. 110(4). 1 indexed citations
20.
Baert, F, G D’Haens, Karel Geboes, Nadine Ectors, & Paul Rutgeerts. (1996). TNF-alpha antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis. Gastroenterology. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alfonso Yubero Breakdown of academic impact, for papers by Robert S. Brody Breakdown of academic impact, for papers by K C Lakshmaiah Breakdown of academic impact, for papers by Madhavan V. Pillai Breakdown of academic impact, for papers by Daniel E. Meyers Breakdown of academic impact, for papers by Shun Yu Breakdown of academic impact, for papers by Wigdan Al-Sukhni Breakdown of academic impact, for papers by S. Pugh Breakdown of academic impact, for papers by Sidrah Khan Breakdown of academic impact, for papers by Nanyan Rao
Rankless by CCL
2026